A major piece of the Inflation Reduction Act provides for negotiations for prescription drug prices for Medicare and out of pocket limits, which has the potential to save Medicare and recipients $29.5 billion per year. But which drugs will be price negotiated? Associate Professor of Clinical Pharmacy at UC San Diego, Inma Hernandez, talks about her independent study into which drugs will be affected in her paper “Drugs Likely Subject to Medicare Negotiation, 2026-2028“.

Did you enjoy this story? Your funding makes great, local journalism like this possible. Donate here